Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer

被引：0
|
作者：
Prince, Emily [1 ]
Pratt, James [2 ]
Novotny, James [2 ]
Chizhevsky, Vladislav [3 ]
Ragheb, Josette William [3 ]
Huron, David [2 ]
机构：
[1] Bristol Myers Squibb, Philadelphia, PA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] NeoGen Labs Inc, Aliso Viejo, CA USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
244
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [31] Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10
    Siefker-Radtke, A. O.
    Hoch, U.
    Loriot, Y.
    Balar, A. V.
    Bilen, M. A.
    Tannir, N. M.
    Cho, D. C.
    Choudhury, A.
    Chien, D.
    Yu, D.
    Currie, S. L.
    Novotny, J.
    Santiago, L.
    Tagliaferri, M. A.
    Zalevsky, J.
    Huddart, R. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S392 - S393
  • [32] Assay performance of the PD-L1 IHC 28-8 pharmDx assay in squamous cell carcinoma of the head and neck (SCCHN).
    Alvarez, Sara
    Hanks, Debra Ann
    William, Josette
    Chan, Joel A.
    Felten, Christopher L.
    Northrup, Adam
    Jaiswal, Dipeshkumar
    Jansson, Malinka
    Phillips, Therese
    Segal, Andrew
    Satnick, Ilana
    McDonald, Hendrick
    Little, Hunter
    Pierce, Coree
    Wynne, Bethany
    Carnahan, Josette
    Reddy, Swarnalatha Y.
    Inzunza, H. David
    Novotny, James
    Oroudjev, Emin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Analysis of real-world PD-L1 testing in patients with urothelial carcinoma.
    Krigsfeld, Gabriel S.
    Prince, Emily
    Zerba, Kim
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Novotny, James
    White, James William
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [34] PD-L1 testing in breast cancer
    Horii, Rie
    ANNALS OF ONCOLOGY, 2023, 34 : S1361 - S1361
  • [35] External Reproducibility of PD-L1 IHC 22C3 pharmDx on Breast Cancer Specimens at CPS ≥ 1 and CPS ≥ 10 Cutoffs
    Steiner, Lori
    Barreto, Joseph
    Olander, Emily
    Kell, Donna
    Tabuena-Frolli, Siena
    Polewski, Monika
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy
    Kim, Hyung-Don
    Shin, Jinho
    Song, In Hye
    Hyung, Jaewon
    Lee, Hyungeun
    Ryu, Min-Hee
    Park, Young Soo
    GASTRIC CANCER, 2024, 27 (04) : 819 - 826
  • [37] EXTERNAL REPRODUCIBILITY OF PD-L1 IHC 22C3 PHARMDX FOR CERVICAL CANCER AT CPS ≥ 1 AND CPS ≥ 10
    Cherryholmes, Greg
    Posch, Alexander
    Tabuena-Frolli, Siena
    Vasquez, Jesse
    Evans, Tiffany
    La Placa, Chris
    Kersch, Kristopher
    Apostolaki, Angeliki
    Juco, Jonathan
    Kulangara, Karina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A44 - A44
  • [38] A comparative study of "PD-L1-CAD-test" (BIOCAD) and "PD-L1 IHC 22C3 pharmDx Kit" (Dako)
    Frank, G.
    Kuznetsova, O.
    Zavalishina, L.
    Andreeva, Y.
    Moskvina, L.
    VIRCHOWS ARCHIV, 2019, 475 : S101 - S102
  • [39] Development of an immunohistochemistry assay for PD-L1 for using the 22C3 antibody in melanoma
    Roach, Charlotte
    Musser, Jeanette
    Ponto, Gary
    Toland, Grant
    Jansson, Malinka
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Stanforth, Dave
    Kulangara, Karina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] A PD-L1 IHC 28-8 PharmDX ring trial on metastatic melanoma: practical aspects
    Siozopoulou, V.
    De Winne, K.
    Smits, E.
    Jacobs, J.
    Zwaenepoel, K.
    Pauwels, P.
    VIRCHOWS ARCHIV, 2019, 475 : S28 - S28
12345